Bristol-Myers Squibb Company
) announced encouraging data from a phase III study
(Hallmark-Dual: n>700) which evaluated the combination of
daclatasvir (DCV: a NS5A inhibitor) and asunaprevir (ASV: a NS3
inhibitor) over 24 weeks in patients infected with genotype 1b
version of hepatitis C virus (HCV). The combination is an
all-oral, interferon and ribavirin-free regimen.
ABBVIE INC (ABBV): Free Stock Analysis Report
AMGEN INC (AMGN): Free Stock Analysis Report
BRISTOL-MYERS (BMY): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.
The percentage of patients who achieved sustained virologic
response at 12 weeks after the completion of the treatment
(SVR12) by the combination constituted the primary end point of
the multinational study. Data from the study revealed that 90%
treatment naïve patients achieved SVR12. The primary objective
was met by 82% patients who failed to respond to
peginterferon/ribavirin therapy. Similarly, 82% patients, who
could not tolerate peginterferon/ribavirin therapy, achieved
SVR12. Moreover, SVR12 rates were found to be roughly similar in
cirrhotic (84%) and non-cirrhotic (85%) patients.
Bristol-Myers said that data from the Hallmark-Dual study formed
part of the package on the basis of which the company sought U.S.
approval for the combination earlier in the week. We note that
Bristol-Myers is looking to get DCV approved in the EU as well in
combination with other agents for treating adults suffering from
HCV with compensated liver disease, inclusive of genotypes 1, 2,
3, and 4. The application is under accelerated review in the EU.
Bristol-Myers is also looking to get the combination of DCV and
ASV approved in Japan for treating adults suffering from genotype
1b version of HCV. The patients were either ineligible for or
intolerant to interferon therapy or non-responders to the same.
Data from the Hallmark-Dual study was comparable to the phase III
study results on the cocktail therapy, which formed the basis of
the submission of the marketing application in that country.
Bristol-Myers stated in its press release that HCV affects
approximately 170 million patients worldwide with a significant
number being affected by the disease in the EU alone. The
prevalence of genotype 1b HCV patients is high in the EU.
Apart from Bristol-Myers, companies such as
) are also developing all-oral, interferon and ribavirin-free HCV
Bristol-Myers currently carries a Zacks Rank #2 (Buy).
) is a better-ranked stock with a Zacks Rank #1 (Strong Buy).